ClinicalTrials.gg
CompletedNCT01908140Updated Mar 7, 2016Results posted

Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of Aclidinium Bromide / Formoterol Fumarate and Salmeterol / Fluticasone in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Completed at 126 sites in 14 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-03-07.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
933
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. aclidinium bromide · Pulmonary Disease, Chronic Obstructive.

Enrollment
6th of 27
933 · median 561
Started
2013
with 1 other
Phase 3
19 of 28
none open now
Registered
20th of 28
by date
Lead sponsor
25 of 28
AstraZeneca

Among the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive, this one is the 6th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2013, is one of 19 in phase 3, and was the 20th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About aclidinium bromide

aclidinium bromide: first FDA approval 2012 (TUDORZA PRESSAIR), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

The purpose of the study is to compare the efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate and salmeterol/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male or non-pregnant, non-lactating female aged ≥40.
  • Current or ex-cigarette smoker, with a smoking history of at least 10 pack-years
  • Patients with a clinical diagnosis of according to GOLD guidelines 2013, with a post-bronchodilator \<80%, and FEV1/FVC \< 70% at Screening Visits
  • Symptomatic patients with a COPD assessment test (CAT) ≥10 at Screening and Randomisation Visits
  • Patient must be able to perform repeatable pulmonary function testing for FEV1 according to ATS/ERS 2005 criteria at Screening Visits
  • Patients eligible and able to participate in the trial and who consent to do so in writing after the purpose and nature of the investigation have been explained

Exclusion criteria

Exclusion Criteria:

  • History or current diagnosis of asthma
  • Development of a respiratory tract infection or exacerbation within 6 weeks (or 3 months if hospitalisation was required) before the Screening Visit or during the run-in period
  • respiratory conditions
  • Type I or uncontrolled Type II diabetes, uncontrolled hypo- or hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled or untreated hypertension
  • Patients who, in the investigator's opinion, may need to start a pulmonary rehabilitation programme during the study and/or patients who started/finished it within 3 months prior to Screening Visit
  • Use of long-term oxygen therapy (≥15 hours/day)
  • Patients treated on daily basis with triple therapy (LABA+LAMA+ICS) within 4 weeks prior to the Screening Visit
  • Patient who does not maintain regular day/night, waking/sleeping cycles including night shift workers
  • Clinically significant cardiovascular conditions
  • Patient with clinically relevant abnormalities in the results of the clinical laboratory tests, parameters or in the physical examination at the Screening Visit
  • Patient with a history of reaction to inhaled anticholinergics, sympathomimetic amines, or inhaled medication or any component thereof (including report of paradoxical bronchospasm)
  • Patient with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute urinary retention, or patients with symptomatic non-stable prostatic hypertrophy
  • Patient with known non-controlled history of infection with (HIV) and/or active hepatitis
  • History of of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer
  • Patient with any other serious or uncontrolled physical or mental dysfunction
  • Patient with a history (within 2 years prior to Screening Visit) of drug and/or alcohol abuse that may prevent study compliance based on investigator judgment
  • Patient unlikely to be cooperative or that can't comply with the study procedures
  • Patient treated with any drug within 30 days (or 6 half-lives, whichever is longer) prior to Screening Visit
  • Patient who intend to use any concomitant medication not permitted by this protocol or who have not undergone the required stabilization periods for prohibited medication
  • Any other conditions that, in the investigator's opinion, might indicate the patient to be unsuitable for the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
933 participants (actual)

Study arms

  • Experimental
    Aclidinium Bromide / Formoterol Fumarate

    Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks

    Drug: Aclidinium Bromide / Formoterol Fumarate

  • Active comparator
    Salmeterol / Fluticasone propionate

    Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks

    Drug: Salmeterol / Fluticasone

Interventions

06

What researchers measure

Primary outcomes

  1. Peak Forced Expiratory Volume in One Second (FEV1) at Week 24

    Peak FEV1 define at the highest value observed in the 3h after the morning IMP administration

    Time frame: At Week 24

Secondary outcomes

  1. Transition Dyspnoea Index (TDI) Focal Score at Week 24

    The TDI includes the same 3 categories as BDI and 7 ratings indicating the magnitude of the change from baseline in each category: from -3 ("major deterioration") to zero ("no change") to +3 ("major improvement"). Category scores are added to compute the Focal Score (from -9 to 9)

    Time frame: At Week 24

07

Results

Posted Mar 7, 2016

Participant flow

This study was conducted at 140 activated sites. A total of 121 sites randomised patients. The first patient was screened in Oct 2013 and the last patient visit was in Aug 2014.

Participant flow — Overall Study
MilestoneAclidinium Bromide / Formoterol FumarateSalmeterol / Fluticasone
Started468465
Completed402386
Not completed6679
Withdrew: Other or progressive disease512
Withdrew: Lack of efficacy75
Withdrew: Withdrawal by subject2324
Withdrew: Lost to follow-up16
Withdrew: Protocol violation89
Withdrew: Adverse event2223

Outcome measures

PrimaryPeak Forced Expiratory Volume in One Second (FEV1) at Week 24

Peak FEV1 define at the highest value observed in the 3h after the morning IMP administration

Time frame:
At Week 24
Reported as:
Least squares mean · Liters
Peak Forced Expiratory Volume in One Second (FEV1) at Week 24
LitersAclidinium Bromide / Formoterol FumarateSalmeterol / Fluticasone
Peak Forced Expiratory Volume in One Second (FEV1) at Week 241.655 ± 0.0111.562 ± 0.011
Statistical analysis
  • Aclidinium Bromide / Formoterol Fumarate vs Salmeterol / Fluticasone · MMRM · p = <0.001 · Mean difference (final values): 0.093 · 95% CI 0.063 to 0.123If non-inferiority on the PP was achieved then switch to superiority was tested on the ITT.
SecondaryTransition Dyspnoea Index (TDI) Focal Score at Week 24

The TDI includes the same 3 categories as BDI and 7 ratings indicating the magnitude of the change from baseline in each category: from -3 ("major deterioration") to zero ("no change") to +3 ("major improvement"). Category scores are added to compute the Focal Score (from -9 to 9)

Time frame:
At Week 24
Reported as:
Least squares mean · TDI Focal Score
Transition Dyspnoea Index (TDI) Focal Score at Week 24
TDI Focal ScoreAclidinium Bromide / Formoterol FumarateSalmeterol / Fluticasone
Transition Dyspnoea Index (TDI) Focal Score at Week 241.9 ± 0.171.9 ± 0.17
Statistical analysis
  • Aclidinium Bromide / Formoterol Fumarate vs Salmeterol / Fluticasone · MMRM · p = >0.05 · Mean difference (final values): -0.001 · 95% CI -0.46 to 0.46

Adverse events

Collected over 24 Weeks treatment + 2 weeks follow-up (±3 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aclidinium Bromide / Formoterol Fumarate—35/467 (7.5%)124/467 (26.6%)
Salmeterol / Fluticasone—33/466 (7.1%)135/466 (29%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventAclidinium Bromide / Formoterol FumarateSalmeterol / Fluticasone
COPD (exacerbation)Respiratory, thoracic and mediastinal disorders13/4678/466
PneumoniaInfections and infestations2/4674/466
Forearm fractureInjury, poisoning and procedural complications0/4672/466
HypertensionVascular disorders0/4672/466
Respiratory failureRespiratory, thoracic and mediastinal disorders2/4670/466
AnaemiaBlood and lymphatic system disorders0/4671/466
Coronary Artery DiseaseCardiac disorders0/4671/466
Cardiac FailureCardiac disorders0/4671/466
Artrial fibrillationCardiac disorders1/4671/466
CataractEye disorders0/4671/466
Most frequent other events
Most frequent other events
EventAclidinium Bromide / Formoterol FumarateSalmeterol / Fluticasone
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders70/46775/466
HeadacheNervous system disorders28/46732/466
NasopharyngitisInfections and infestations26/46728/466

Baseline characteristics

Patients with more than 1 treatment were analysed in the Safety population with the actual treatment assigned; for this reason, the Overall Number of Baseline Participants in the safety population is different than the randomised population.

Age, Customized
Age, Customized(years)Aclidinium Bromide / Formoterol FumarateSalmeterol / FluticasoneTotal
Age (years), mean (SD)63.5 ± 8.163.3 ± 7.563.4 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Aclidinium Bromide / Formoterol FumarateSalmeterol / FluticasoneTotal
Female160166326
Male307300607
Region of Enrollment
Region of Enrollment(participants)Aclidinium Bromide / Formoterol FumarateSalmeterol / FluticasoneTotal
Austria232447
Bulgaria303262
Canada12618
Czech Republic111425
France10414
Germany118136254
Hungary504898
Italy6511
Lithuania171027
Netherlands111122
Poland6755122
South Africa6866134
Spain283462
United Kingdom162137
08

Study locations

126 sites
  • Almirall Investigational Site
    Feldbach, 8330, Austria
  • Almirall Investigational Site
    Feldkirch, 6800, Austria
  • Almirall Investigational Site
    Grieskirchen, A-4710, Austria
  • Almirall Investigational Site
    Linz, 4020, Austria
  • Almirall Investigational Site
    Salzburg, 5020, Austria
  • Almirall Investigational Site
    Dimitrovgrad, 6400, Bulgaria
  • Almirall Investigational Site
    Gabrovo, 5300, Bulgaria
  • Almirall Investigational Site
    Kozlodui, 3320, Bulgaria
  • Almirall Investigational Site
    Petrich, 2850, Bulgaria
  • Almirall Investigational Site
    Plovdiv, 4000, Bulgaria
  • Almirall Investigational Site
    Razgrad, 7200, Bulgaria
  • Almirall Investigational Site
    Stara Zagora, 6003, Bulgaria
  • Almirall Investigational Site
    Vidin, 3700, Bulgaria
  • Almirall Investigational Site
    Edmonton, Alberta AB T6G 2B7, Canada
  • Almirall Investigational Site
    Vancouver, British Columbia BC V5Z 1M9, Canada
  • Almirall Investigational Site
    Vancouver, British Columbia BC V7M 2H9, Canada
  • Almirall Investigational Site
    Moncton, New Brunswick NB E1C 5K4, Canada
  • Almirall Investigational Site
    Toronto, Ontario ON M6H 3M2, Canada
  • Almirall Investigational Site
    Saint Romuald, Quebec QC G6W 5M6, Canada
  • Almirall Investigational Site
    Trois-Rivières, Quebec QC G8T 7A1, Canada
  • Almirall Investigational Site
    Karlovy Vary, 360 09, Czech Republic
  • Almirall Investigational Site
    Kralupy nad Vltavou, 278 01, Czech Republic
  • Almirall Investigational Site
    Liberec, 460 63, Czech Republic
  • Almirall Investigational Site
    Ostrava - Hrabuvka, 700 30, Czech Republic
  • Almirall Investigational Site
    Rokycany, 337 01, Czech Republic
  • Almirall Investigational Site
    Strakonice, 386 01, Czech Republic
  • Almirall Investigational Site
    Nîmes, 30900, France
  • Almirall Investigational Site
    Perpignan, 66025, France
  • Almirall Investigational Site
    Vieux Conde, 59690, France
  • Almirall Investigational Site
    Berlin, 10117, Germany
  • Almirall Investigational Site
    Berlin, 10629, Germany
  • Almirall Investigational Site
    Berlin, 10717, Germany
  • Almirall Investigational Site
    Berlin, 10969, Germany
  • Almirall Investigational Site
    Berlin, 12043, Germany
  • Almirall Investigational Site
    Berlin, 13125, Germany
  • Almirall Investigational Site
    Berlin, 13581, Germany
  • Almirall Investigational Site
    Berlin, 14059, Germany
  • Almirall Investigational Site
    Bochum, 44789, Germany
  • Almirall Investigational Site
    Bonn, 53123, Germany
  • Almirall Investigational Site
    Cologne, 51069, Germany
  • Almirall Investigational Site
    Cottbus, 03050, Germany
  • Almirall Investigational Site
    Dortmund, 44263, Germany
  • Almirall Investigational Site
    Dresden, 01307, Germany
  • Almirall Investigational Site
    Frankfurt, 60389, Germany
  • Almirall Investigational Site
    Frankfurt, 60596, Germany
  • Almirall Investigational Site
    Gauting, 82131, Germany
  • Almirall Investigational Site
    Großhansdorf, 22927, Germany
  • Almirall Investigational Site
    Hamburg, 20253, Germany
  • Almirall Investigational Site
    Hamburg, 20354, Germany
  • Almirall Investigational Site
    Hamburg, 22143, Germany
  • Almirall Investigational Site
    Hannover, 30159, Germany
  • Almirall Investigational Site
    Jena, 07740, Germany
  • Almirall Investigational Site
    Leipzig, 4357, Germany
  • Almirall Investigational Site
    Marburg, 35037, Germany
  • Almirall Investigational Site
    Munich, 80539, Germany
  • Almirall Investigational Site
    Rüdersdorf, 15562, Germany
  • Almirall Investigational Site
    Schwabach, 91126, Germany
  • Almirall Investigational Site
    Wiesbaden, 65187, Germany
  • Almirall Investigational Site
    Wiesloch, 69168, Germany
  • Almirall Investigational Site
    Witten, 58452, Germany
  • Almirall Investigational Site
    Balassagyarmat, 2660, Hungary
  • Almirall Investigational Site
    Budapest, 1191, Hungary
  • Almirall Investigational Site
    Budapest, 1204, Hungary
  • Almirall Investigational Site
    Debrecen, H-4032, Hungary
  • Almirall Investigational Site
    Komárom, 2900, Hungary
  • Almirall Investigational Site
    Nyíregyháza, 4400, Hungary
  • Almirall Investigational Site
    Pécs, H-7635, Hungary
  • Almirall Investigational Site
    Szazhalombatta, H-2400, Hungary
  • Almirall Investigational Site
    Szigetszentmiklós, H-2310, Hungary
  • Almirall Investigational Site
    Vásárosnamény, 4800, Hungary
  • Almirall Investigational Site
    Pisa, 56124, Italy
  • Almirall Investigational Site
    Pordenone, 33170, Italy
  • Almirall Investigational Site
    Trieste, 34149, Italy
  • Almirall Investigational Site
    Kaunas, LT-50009, Lithuania
  • Almirall Investigational Site
    Klaipeda, LT-92231, Lithuania
  • Almirall Investigational Site
    Klaipeda, LT-92288, Lithuania
  • Almirall Investigational Site
    Vilnius, LT-01117, Lithuania
  • Almirall Investigational Site
    Almere, 1311 RL, Netherlands
  • Almirall Investigational Site
    Beek, 6191 JW, Netherlands
  • Almirall Investigational Site
    Eindhoven, 5623 EJ, Netherlands
  • Almirall Investigational Site
    Hoofddorp, 2134, Netherlands
  • Almirall Investigational Site
    Leeuwarden, 8934 AD, Netherlands
  • Almirall Investigational Site
    Rotterdam, 3045 PM, Netherlands
  • Almirall Investigational Site
    Bialystok, 15-010, Poland
  • Almirall Investigational Site
    Bialystok, 15-044, Poland
  • Almirall Investigational Site
    Bialystok, 15-270, Poland
  • Almirall Investigational Site
    Gdansk, 80-847, Poland
  • Almirall Investigational Site
    Katowice, 40-752, Poland
  • Almirall Investigational Site
    Krakow, 31-455, Poland
  • Almirall Investigational Site
    Lodz, 90-242, Poland
  • Almirall Investigational Site
    Ostrowiec Swietokrzyski, 27-400, Poland
  • Almirall Investigational Site
    Pila, 64-920, Poland
  • Almirall Investigational Site
    Poznan, 60-214, Poland
  • Almirall Investigational Site
    Proszowice, 32-100, Poland
  • Almirall Investigational Site
    Sopot, 81-741, Poland
  • Almirall Investigational Site
    Szczecin, 71-124, Poland
  • Almirall Investigational Site
    Tarnow, 33-100, Poland
  • Almirall Investigational Site
    Tczew, 83-110, Poland
  • Almirall Investigational Site
    Warsaw, 01-138, Poland
  • Almirall Investigational Site
    Wilkowice-Bystra, 43-365, Poland

Showing the first 100 of 126 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten AM, Beier J, Seoane B, Segarra RM, Leselbaum A. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J. 2016 Oct;48(4):1030-1039. doi: 10.1183/13993003.00216-2016. Epub 2016 Aug 4. PubMed 27492833 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2013
First posted
Jul 25, 2013
Start
Sep 2013
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Mar 7, 2016
Last update
Mar 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01908140
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 25, 2013
Start date
Sep 2013
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Mar 7, 2016
Last update
Mar 7, 2016

Study contacts

Esther Garcia, Ph.D.
study director · Global Medicines Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aclidinium bromide · Formoterol

Start the discussion